Barry R. Davis, MD, PhD

Dr. Barry Davis, Guy S. Parcel Chair in Public Health, Professor of Biostatistics, and Director of the Coordinating Center for Clinical Trials at The University of Texas School of Public Health, has co-authored more than 300 peer-reviewed publications, and is highly regarded nationally and internationally for his contributions to clinical trials.

Show full bio

Dr. Davis has extensive experience in the leadership, design, analysis, oversight, and data management of multicenter clinical trials. He is past President and a Fellow of the Society for Clinical Trials. During the last 30 years, Dr. Davis has participated in and led numerous large-scale cardiovascular (particularly hypertension) clinical trials. Specifically, as PI or Co-I in the NHLBI sponsored Hypertension Detection and Follow-up Program (HDFP), Systolic Hypertension in the Elderly Program (SHEP), Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT, a world renowned pragmatic trial), and Genetics of Hypertension Associated Treatment (GenHAT) and in the industry-sponsored Cholesterol and Recurrent Events Trial (CARE).

Dr. Davis’ research has garnered over $200 million in extramural funding. He is a Fellow of the American Statistical Association and the American Association for the Advancement of Science and has served on numerous Data Monitoring Committees.

Hide full bio

See Publications

Interests

Clinical Trials
Hypertension
Regenerative Medicine

Education

Undergraduate:

Massachusetts Institute of Technology
Postgraduate:

Brown University
Medical School:

University of California San Diego School of Medicine
Internship:

Worcester City Hospital, University of Massachusetts

Academic & Clinical Affiliations

The University of Texas School of Public Health

Certifications

American Board of Preventative Health and General Preventative Medicine

Honors, Awards and Memberships

The Texas Heart Institute Academic Professional Staff
President, Society for Clinical Trials
Fellow, American Association for the Advancement of Science
Fellow, American Statistical Association

Publications

4862227 HVXNQK65 1 alternatives-to-animal-experimentation 10 date desc Davis 1882 https://www.texasheart.org/wp-content/plugins/zotpress/

%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3Afalse%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%22NK5QXPWZ%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Bidel%20et%20al.%22%2C%22parsedDate%22%3A%222023-07-24%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BBidel%2C%20Z.%2C%20Nazarzadeh%2C%20M.%2C%20Canoy%2C%20D.%20et%20al.%20%282023%29.%20Sex-specific%20effects%20of%20blood%20pressure%20lowering%20pharmacotherapy%20for%20the%20prevention%20of%20cardiovascular%20disease%3A%20an%20individual%20participant-level%20data%20meta-analysis.%20%26lt%3Bi%26gt%3BHypertension%26lt%3B%5C%2Fi%26gt%3B.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1161%5C%2FHYPERTENSIONAHA.123.21496%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1161%5C%2FHYPERTENSIONAHA.123.21496%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Sex-specific%20effects%20of%20blood%20pressure%20lowering%20pharmacotherapy%20for%20the%20prevention%20of%20cardiovascular%20disease%3A%20an%20individual%20participant-level%20data%20meta-analysis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Zeinab%22%2C%22lastName%22%3A%22Bidel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Milad%22%2C%22lastName%22%3A%22Nazarzadeh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dexter%22%2C%22lastName%22%3A%22Canoy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emma%22%2C%22lastName%22%3A%22Copland%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eva%22%2C%22lastName%22%3A%22Gerdts%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mark%22%2C%22lastName%22%3A%22Woodward%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ajay%20K.%22%2C%22lastName%22%3A%22Gupta%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christopher%20M.%22%2C%22lastName%22%3A%22Reid%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22William%20C.%22%2C%22lastName%22%3A%22Cushman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kristian%22%2C%22lastName%22%3A%22Wachtell%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Koon%22%2C%22lastName%22%3A%22Teo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Barry%20R.%22%2C%22lastName%22%3A%22Davis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22John%22%2C%22lastName%22%3A%22Chalmers%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carl%20J.%22%2C%22lastName%22%3A%22Pepine%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kazem%22%2C%22lastName%22%3A%22Rahimi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22Blood%20Pressure%20Lowering%20Treatment%20Trialists%5Cu2019%20Collaboration%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Whether%20the%20relative%20effects%20of%20blood%20pressure%20%28BP%29-lowering%20treatment%20on%20cardiovascular%20outcomes%20differ%20by%20sex%2C%20particularly%20when%20BP%20is%20not%20substantially%20elevated%2C%20has%20been%20uncertain.%5CnMETHODS%3A%20We%20conducted%20an%20individual%20participant-level%20data%20meta-analysis%20of%20randomized%20controlled%20trials%20of%20pharmacological%20BP%20lowering.%20We%20pooled%20the%20data%20and%20categorized%20participants%20by%20sex%2C%20systolic%20BP%20categories%20in%2010-mm%5Cu2009Hg%20increments%20from%20%26lt%3B120%20to%20%5Cu2265170%20mm%5Cu2009Hg%2C%20and%20age%20categories%20spanning%20from%20%26lt%3B55%20to%20%5Cu226585%20years.%20We%20used%20fixed-effect%201-stage%20individual%20participant-level%20data%20meta-analyses%20and%20applied%20Cox%20proportional%20hazard%20models%2C%20stratified%20by%20trial%2C%20to%20analyze%20the%20data.%5CnRESULTS%3A%20We%20included%20data%20from%2051%20randomized%20controlled%20trials%20involving%20358%5Cu2005635%20%2842%25%20women%29%20participants.%20Over%204.2%20years%20of%20median%20follow-up%2C%20a%205-mm%5Cu2009Hg%20reduction%20in%20systolic%20BP%20decreased%20the%20risk%20of%20major%20cardiovascular%20events%20both%20in%20women%20and%20men%20%28hazard%20ratio%20%5B95%25%20CI%5D%2C%200.92%20%5B0.89-0.95%5D%20for%20women%20and%200.90%20%5B0.88-0.93%5D%20for%20men%3B%20P%20for%20interaction%2C%201%29.%20There%20was%20no%20evidence%20for%20heterogeneity%20of%20relative%20treatment%20effects%20by%20sex%20for%20the%20major%20cardiovascular%20disease%2C%20its%20components%2C%20or%20across%20the%20different%20baseline%20BP%20categories%20%28all%20P%20for%20interaction%2C%20%5Cu22650.57%29.%20The%20effects%20in%20women%20and%20men%20were%20consistent%20across%20age%20categories%20and%20the%20types%20of%20antihypertensive%20medications%20%28all%20P%20for%20interaction%2C%20%5Cu22650.14%29.%5CnCONCLUSIONS%3A%20The%20effects%20of%20BP%20reduction%20were%20similar%20in%20women%20and%20men%20across%20all%20BP%20and%20age%20categories%20at%20randomization%20and%20with%20no%20evidence%20to%20suggest%20that%20drug%20classes%20had%20differing%20effects%20by%20sex.%20This%20study%20does%20not%20substantiate%20sex-based%20differences%20in%20BP-lowering%20treatment.%22%2C%22date%22%3A%222023-07-24%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1161%5C%2FHYPERTENSIONAHA.123.21496%22%2C%22ISSN%22%3A%221524-4563%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22HVXNQK65%22%2C%22LIMU9MDX%22%5D%2C%22dateModified%22%3A%222023-07-27T16%3A56%3A57Z%22%7D%7D%2C%7B%22key%22%3A%22NYVCHIIE%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Ghosh%20et%20al.%22%2C%22parsedDate%22%3A%222022-12-20%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BGhosh%2C%20A.%2C%20Chan%2C%20W.%2C%20Younes%2C%20N.%20et%20al.%20%282022%29.%20A%20dynamic%20risk%20model%20for%20multitype%20recurrent%20events.%20%26lt%3Bi%26gt%3BAm%20J%20Epidemiol%26lt%3B%5C%2Fi%26gt%3B%2C%20kwac213.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Faje%5C%2Fkwac213%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Faje%5C%2Fkwac213%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22A%20dynamic%20risk%20model%20for%20multitype%20recurrent%20events%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alokananda%22%2C%22lastName%22%3A%22Ghosh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Wenyaw%22%2C%22lastName%22%3A%22Chan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Naji%22%2C%22lastName%22%3A%22Younes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Barry%20R.%22%2C%22lastName%22%3A%22Davis%22%7D%5D%2C%22abstractNote%22%3A%22Recurrent%20events%20can%20occur%20more%20than%20once%20in%20the%20same%20individual%3B%20such%20events%20may%20be%20of%20different%20types%2C%20known%20as%20multi-type%20recurrent%20events.%20They%20are%20very%20common%20in%20longitudinal%20studies.%20Often%20there%20is%20a%20terminating%20event%2C%20after%20which%20no%20further%20events%20can%20occur.%20The%20risk%20of%20any%20event%20including%20terminating%20events%20such%20as%20death%20or%20cure%20is%20typically%20affected%20by%20prior%20events.%20We%20propose%20a%20flexible%20joint%20multi-type%20recurrent%20events%20model%20that%20explicitly%20provides%20estimates%20of%20the%20change%20in%20risk%20for%20each%20event%20due%20to%20subject%20characteristics%20including%20number%20and%20type%20of%20prior%20events%2C%20the%20absolute%20risk%20for%20every%20event%20type%2C%20terminating%20and%20nonterminating%2C%20and%20predicts%20event-free%20survival%20probability%20over%20a%20desired%20time%20period.%20The%20model%20is%20fully%20parametric%20and%20therefore%20a%20standard%20likelihood%20function%20and%20robust%20standard%20errors%20can%20be%20constructed.%20We%20illustrate%20the%20model%20with%20applications%20to%20the%20Antihypertensive%20and%20Lipid-Lowering%20Treatment%20to%20Prevent%20Heart%20Attack%20Trial%20%281994-2002%29%20and%20provide%20discussion%20of%20the%20results%20and%20model%20features.%22%2C%22date%22%3A%22Dec%2020%2C%202022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1093%5C%2Faje%5C%2Fkwac213%22%2C%22ISSN%22%3A%221476-6256%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22HVXNQK65%22%2C%22JD5ZU4IS%22%5D%2C%22dateModified%22%3A%222023-03-14T14%3A33%3A21Z%22%7D%7D%2C%7B%22key%22%3A%2259VJ5DBZ%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Nazarzadeh%20et%20al.%22%2C%22parsedDate%22%3A%222022-07-22%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BNazarzadeh%2C%20M.%2C%20Bidel%2C%20Z.%2C%20Canoy%2C%20D.%20et%20al.%20%282022%29.%20Blood%20pressure-lowering%20treatment%20for%20prevention%20of%20major%20cardiovascular%20diseases%20in%20people%20with%20and%20without%20type%202%20diabetes%3A%20an%20individual%20participant-level%20data%20meta-analysis.%20%26lt%3Bi%26gt%3BLancet%20Diabetes%20Endocrinol%26lt%3B%5C%2Fi%26gt%3B%2C%20S2213-8587%2822%2900172%26%23x2013%3B3.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2FS2213-8587%2822%2900172-3%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2FS2213-8587%2822%2900172-3%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Blood%20pressure-lowering%20treatment%20for%20prevention%20of%20major%20cardiovascular%20diseases%20in%20people%20with%20and%20without%20type%202%20diabetes%3A%20an%20individual%20participant-level%20data%20meta-analysis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Milad%22%2C%22lastName%22%3A%22Nazarzadeh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Zeinab%22%2C%22lastName%22%3A%22Bidel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dexter%22%2C%22lastName%22%3A%22Canoy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emma%22%2C%22lastName%22%3A%22Copland%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Derrick%20A.%22%2C%22lastName%22%3A%22Bennett%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Abbas%22%2C%22lastName%22%3A%22Dehghan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22George%22%2C%22lastName%22%3A%22Davey%20Smith%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rury%20R.%22%2C%22lastName%22%3A%22Holman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mark%22%2C%22lastName%22%3A%22Woodward%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ajay%22%2C%22lastName%22%3A%22Gupta%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Amanda%20I.%22%2C%22lastName%22%3A%22Adler%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Malgorzata%22%2C%22lastName%22%3A%22Wamil%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Naveed%22%2C%22lastName%22%3A%22Sattar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22William%20C.%22%2C%22lastName%22%3A%22Cushman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Richard%20J.%22%2C%22lastName%22%3A%22McManus%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Koon%22%2C%22lastName%22%3A%22Teo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Barry%20R.%22%2C%22lastName%22%3A%22Davis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22John%22%2C%22lastName%22%3A%22Chalmers%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carl%20J.%22%2C%22lastName%22%3A%22Pepine%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kazem%22%2C%22lastName%22%3A%22Rahimi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22Blood%20Pressure%20Lowering%20Treatment%20Trialists%27%20Collaboration%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Controversy%20exists%20as%20to%20whether%20the%20threshold%20for%20blood%20pressure-lowering%20treatment%20should%20differ%20between%20people%20with%20and%20without%20type%202%20diabetes.%20We%20aimed%20to%20investigate%20the%20effects%20of%20blood%20pressure-lowering%20treatment%20on%20the%20risk%20of%20major%20cardiovascular%20events%20by%20type%202%20diabetes%20status%2C%20as%20well%20as%20by%20baseline%20levels%20of%20systolic%20blood%20pressure.%5CnMETHODS%3A%20We%20conducted%20a%20one-stage%20individual%20participant-level%20data%20meta-analysis%20of%20major%20randomised%20controlled%20trials%20using%20the%20Blood%20Pressure%20Lowering%20Treatment%20Trialists%26%23039%3B%20Collaboration%20dataset.%20Trials%20with%20information%20on%20type%202%20diabetes%20status%20at%20baseline%20were%20eligible%20if%20they%20compared%20blood%20pressure-lowering%20medications%20versus%20placebo%20or%20other%20classes%20of%20blood%20pressure-lowering%20medications%2C%20or%20an%20intensive%20versus%20a%20standard%20blood%20pressure-lowering%20strategy%2C%20and%20reported%20at%20least%201000%20persons-years%20of%20follow-up%20in%20each%20group.%20Trials%20exclusively%20on%20participants%20with%20heart%20failure%20or%20with%20short-term%20therapies%20and%20acute%20myocardial%20infarction%20or%20other%20acute%20settings%20were%20excluded.%20We%20expressed%20treatment%20effect%20per%205%20mm%20Hg%20reduction%20in%20systolic%20blood%20pressure%20on%20the%20risk%20of%20developing%20a%20major%20cardiovascular%20event%20as%20the%20primary%20outcome%2C%20defined%20as%20the%20first%20occurrence%20of%20fatal%20or%20non-fatal%20stroke%20or%20cerebrovascular%20disease%2C%20fatal%20or%20non-fatal%20ischaemic%20heart%20disease%2C%20or%20heart%20failure%20causing%20death%20or%20requiring%20hospitalisation.%20Cox%20proportional%20hazard%20models%2C%20stratified%20by%20trial%2C%20were%20used%20to%20estimate%20hazard%20ratios%20%28HRs%29%20separately%20by%20type%202%20diabetes%20status%20at%20baseline%2C%20with%20further%20stratification%20by%20baseline%20categories%20of%20systolic%20blood%20pressure%20%28in%2010%20mm%20Hg%20increments%20from%20%26lt%3B120%20mm%20Hg%20to%20%5Cu2265170%20mm%20Hg%29.%20To%20estimate%20absolute%20risk%20reductions%2C%20we%20used%20a%20Poisson%20regression%20model%20over%20the%20follow-up%20duration.%20The%20effect%20of%20each%20of%20the%20five%20major%20blood%20pressure-lowering%20drug%20classes%2C%20including%20angiotensin-converting%20enzyme%20inhibitors%2C%20angiotensin%20II%20receptor%20blockers%2C%20%5Cu03b2%20blockers%2C%20calcium%20channel%20blockers%2C%20and%20thiazide%20diuretics%2C%20was%20estimated%20using%20a%20network%20meta-analysis%20framework.%20This%20study%20is%20registered%20with%20PROSPERO%2C%20CRD42018099283.%5CnFINDINGS%3A%20We%20included%20data%20from%2051%20randomised%20clinical%20trials%20published%20between%201981%20and%202014%20involving%20358%5Cu2009533%20participants%20%2858%25%20men%29%2C%20among%20whom%20103%5Cu2009325%20%2829%25%29%20had%20known%20type%202%20diabetes%20at%20baseline.%20The%20baseline%20mean%20systolic%5C%2Fdiastolic%20blood%20pressure%20of%20those%20with%20and%20without%20type%202%20diabetes%20was%20149%5C%2F84%20mm%20Hg%20%28SD%2019%5C%2F11%29%20and%20153%5C%2F88%20mm%20Hg%20%28SD%2021%5C%2F12%29%2C%20respectively.%20Over%204%5Cu00b72%20years%20median%20follow-up%20%28IQR%203%5Cu00b70-5%5Cu00b70%29%2C%20a%205%20mm%20Hg%20reduction%20in%20systolic%20blood%20pressure%20decreased%20the%20risk%20of%20major%20cardiovascular%20events%20in%20both%20groups%2C%20but%20with%20a%20weaker%20relative%20treatment%20effect%20in%20participants%20with%20type%202%20diabetes%20%28HR%200%5Cu00b794%20%5B95%25%20CI%200%5Cu00b791-0%5Cu00b798%5D%29%20compared%20with%20those%20without%20type%202%20diabetes%20%280%5Cu00b789%20%5B0%5Cu00b787-0%5Cu00b792%5D%3B%20pinteraction%3D0%5Cu00b70013%29.%20However%2C%20absolute%20risk%20reductions%20did%20not%20differ%20substantially%20between%20people%20with%20and%20without%20type%202%20diabetes%20because%20of%20the%20higher%20absolute%20cardiovascular%20risk%20among%20participants%20with%20type%202%20diabetes.%20We%20found%20no%20reliable%20evidence%20for%20heterogeneity%20of%20treatment%20effects%20by%20baseline%20systolic%20blood%20pressure%20in%20either%20group.%20In%20keeping%20with%20the%20primary%20findings%2C%20analysis%20using%20stratified%20network%20meta-analysis%20showed%20no%20evidence%20that%20relative%20treatment%20effects%20differed%20substantially%20between%20participants%20with%20type%202%20diabetes%20and%20those%20without%20for%20any%20of%20the%20drug%20classes%20investigated.%5CnINTERPRETATION%3A%20Although%20the%20relative%20beneficial%20effects%20of%20blood%20pressure%20reduction%20on%20major%20cardiovascular%20events%20were%20weaker%20in%20participants%20with%20type%202%20diabetes%20than%20in%20those%20without%2C%20absolute%20effects%20were%20similar.%20The%20difference%20in%20relative%20risk%20reduction%20was%20not%20related%20to%20the%20baseline%20blood%20pressure%20or%20allocation%20to%20different%20drug%20classes.%20Therefore%2C%20the%20adoption%20of%20differential%20blood%20pressure%20thresholds%2C%20intensities%20of%20blood%20pressure%20lowering%2C%20or%20drug%20classes%20used%20in%20people%20with%20and%20without%20type%202%20diabetes%20is%20not%20warranted.%5CnFUNDING%3A%20British%20Heart%20Foundation%2C%20UK%20National%20Institute%20for%20Health%20Research%2C%20and%20Oxford%20Martin%20School.%22%2C%22date%22%3A%22Jul%2022%202022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2FS2213-8587%2822%2900172-3%22%2C%22ISSN%22%3A%222213-8595%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22HVXNQK65%22%2C%222RCWVZ4F%22%5D%2C%22dateModified%22%3A%222022-08-02T14%3A39%3A08Z%22%7D%7D%2C%7B%22key%22%3A%22GIAZCVQ9%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Kaushal%20et%20al.%22%2C%22parsedDate%22%3A%222022-04-08%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BKaushal%2C%20S.%2C%20Hare%2C%20J.%20M.%2C%20Shah%2C%20A.%20M.%20et%20al.%20%282022%29.%20Autologous%20cardiac%20stem%20cell%20injection%20in%20patients%20with%20hypoplastic%20left%20heart%20syndrome%20%28CHILD%20Study%29.%20%26lt%3Bi%26gt%3BPediatr%20Cardiol%26lt%3B%5C%2Fi%26gt%3B.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs00246-022-02872-6%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs00246-022-02872-6%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Autologous%20cardiac%20stem%20cell%20injection%20in%20patients%20with%20hypoplastic%20left%20heart%20syndrome%20%28CHILD%20Study%29%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sunjay%22%2C%22lastName%22%3A%22Kaushal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joshua%20M.%22%2C%22lastName%22%3A%22Hare%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aakash%20M.%22%2C%22lastName%22%3A%22Shah%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicholas%20P.%22%2C%22lastName%22%3A%22Pietris%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Judith%20L.%22%2C%22lastName%22%3A%22Bettencourt%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Linda%20B.%22%2C%22lastName%22%3A%22Piller%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aisha%22%2C%22lastName%22%3A%22Khan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Abigail%22%2C%22lastName%22%3A%22Snyder%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Riley%20M.%22%2C%22lastName%22%3A%22Boyd%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mohamed%22%2C%22lastName%22%3A%22Abdullah%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rachana%22%2C%22lastName%22%3A%22Mishra%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sudhish%22%2C%22lastName%22%3A%22Sharma%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Timothy%20C.%22%2C%22lastName%22%3A%22Slesnick%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ming-Sing%22%2C%22lastName%22%3A%22Si%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Paul%20J.%22%2C%22lastName%22%3A%22Chai%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Barry%20R.%22%2C%22lastName%22%3A%22Davis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dejian%22%2C%22lastName%22%3A%22Lai%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%20E.%22%2C%22lastName%22%3A%22Davis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22William%20T.%22%2C%22lastName%22%3A%22Mahle%22%7D%5D%2C%22abstractNote%22%3A%22Mortality%20in%20infants%20with%20hypoplastic%20left%20heart%20syndrome%20%28HLHS%29%20is%20strongly%20correlated%20with%20right%20ventricle%20%28RV%29%20dysfunction.%20Cell%20therapy%20has%20demonstrated%20potential%20improvements%20of%20RV%20dysfunction%20in%20animal%20models%20related%20to%20HLHS%2C%20and%20neonatal%20human%20derived%20c-kit%2B%20cardiac-derived%20progenitor%20cells%20%28CPCs%29%20show%20superior%20efficacy%20when%20compared%20to%20adult%20human%20cardiac-derived%20CPCs%20%28aCPCs%29.%20Neonatal%20CPCs%20%28nCPCs%29%20have%20yet%20to%20be%20investigated%20in%20humans.%20The%20CHILD%20trial%20%28Autologous%20Cardiac%20Stem%20Cell%20Injection%20in%20Patients%20with%20Hypoplastic%20Left%20Heart%20Syndrome%29%20is%20a%20Phase%20I%5C%2FII%20trial%20aimed%20at%20investigating%20intramyocardial%20administration%20of%20autologous%20nCPCs%20in%20HLHS%20infants%20by%20assessing%20the%20feasibility%2C%20safety%2C%20and%20potential%20efficacy%20of%20CPC%20therapy.%20Using%20an%20open-label%2C%20multicenter%20design%2C%20CHILD%20investigates%20nCPC%20safety%20and%20feasibility%20in%20the%20first%20enrollment%20group%20%28Group%20A%5C%2FPhase%20I%29.%20In%20the%20second%20enrollment%20group%2C%20CHILD%20uses%20a%20randomized%2C%20double-blinded%2C%20multicenter%20design%20%28Group%20B%5C%2FPhase%20II%29%2C%20to%20assess%20nCPC%20efficacy%20based%20on%20RV%20functional%20and%20structural%20characteristics.%20The%20study%20plans%20to%20enroll%2032%20patients%20across%204%20institutions%3A%20Group%20A%20will%20enroll%2010%20patients%2C%20and%20Group%20B%20will%20enroll%2022%20patients.%20CHILD%20will%20provide%20important%20insights%20into%20the%20therapeutic%20potential%20of%20nCPCs%20in%20patients%20with%20HLHS.Clinical%20Trial%20Registration%20https%3A%5C%2F%5C%2Fclinicaltrials.gov%5C%2Fct2%5C%2Fhome%20NCT03406884%2C%20First%20posted%20January%2023%2C%202018.%22%2C%22date%22%3A%22Apr%208%202022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1007%5C%2Fs00246-022-02872-6%22%2C%22ISSN%22%3A%221432-1971%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22HVXNQK65%22%2C%22ZH6PLEMG%22%5D%2C%22dateModified%22%3A%222022-05-04T15%3A22%3A11Z%22%7D%7D%2C%7B%22key%22%3A%225AHNUECE%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Nazarzadeh%20et%20al.%22%2C%22parsedDate%22%3A%222022-02-25%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BNazarzadeh%2C%20M.%2C%20Canoy%2C%20D.%2C%20Bidel%2C%20Z.%20et%20al.%20%282022%29.%20The%20Blood%20Pressure%20Lowering%20Treatment%20Trialists%26%23x2019%3B%20Collaboration%3A%20Methodological%20clarifications%20of%20recent%20reports.%20%26lt%3Bi%26gt%3BJ%20Hypertens%26lt%3B%5C%2Fi%26gt%3B.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FHJH.0000000000003107%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FHJH.0000000000003107%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22The%20Blood%20Pressure%20Lowering%20Treatment%20Trialists%27%20Collaboration%3A%20Methodological%20clarifications%20of%20recent%20reports%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Milad%22%2C%22lastName%22%3A%22Nazarzadeh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dexter%22%2C%22lastName%22%3A%22Canoy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Zeinab%22%2C%22lastName%22%3A%22Bidel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emma%22%2C%22lastName%22%3A%22Copland%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kazem%22%2C%22lastName%22%3A%22Rahimi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Koon%22%2C%22lastName%22%3A%22Teo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Barry%20R.%22%2C%22lastName%22%3A%22Davis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22John%22%2C%22lastName%22%3A%22Chalmers%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carl%20J.%22%2C%22lastName%22%3A%22Pepine%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mark%22%2C%22lastName%22%3A%22Woodward%22%7D%5D%2C%22abstractNote%22%3A%22Epidemiological%20evidence%20has%20consistently%20shown%20that%20people%20with%20higher%20systolic%20or%20diastolic%20blood%20pressure%20are%20at%20greater%20risk%20of%20cardiovascular%20diseases.%20However%2C%20there%20has%20been%20limited%20randomized%20evidence%20to%20determine%20the%20role%20of%20blood%20pressure%20level%20at%20treatment%20initiation%20in%20the%20reduction%20of%20cardiovascular%20diseases%20risk.%20The%20extent%20to%20which%20other%20characteristics%20of%20individuals%2C%20such%20as%20prior%20disease%20history%2C%20age%20or%20sex%2C%20should%20be%20taken%20into%20account%20has%20also%20been%20controversial.%20Furthermore%2C%20effects%20on%20less%20commonly%20reported%20efficacy%20and%20safety%20outcomes%20remain%20underexplored.%20The%20Blood%20Pressure%20Lowering%20Treatment%20Trialists%26%23039%3B%20Collaboration%20has%20collected%20individual-level%20participant%20data%20from%2052%20randomized%20clinical%20trials%2C%20with%20more%20than%20360%5Cu200a000%20participants%2C%20and%20is%20now%20the%20largest%20source%20of%20individual-level%20data%20from%20randomized%20clinical%20trials%20of%20blood%20pressure-lowering%20treatment.%20This%20resource%20provides%20an%20unprecedented%20opportunity%20to%20address%20major%20areas%20of%20uncertainty%20relating%20to%20stratified%20efficacy%20and%20safety%20of%20antihypertensive%20therapy.%20Recent%20reports%20have%20demonstrated%20the%20power%20of%20pooled%20analyses%20of%20the%20Blood%20Pressure%20Lowering%20Treatment%20Trialists%26%23039%3B%20Collaboration%20dataset%20in%20filling%20long-standing%20gaps%20in%20our%20knowledge.%20However%2C%20there%20have%20been%20some%20misconceptions%20regarding%20the%20methods%20underpinning%20the%20recent%20reports%2C%20which%20we%20clarify%20in%20this%20article.%22%2C%22date%22%3A%22Feb%2025%202022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1097%5C%2FHJH.0000000000003107%22%2C%22ISSN%22%3A%221473-5598%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22HVXNQK65%22%2C%22LNSKD4V3%22%5D%2C%22dateModified%22%3A%222022-03-29T18%3A42%3A24Z%22%7D%7D%2C%7B%22key%22%3A%22EI8YQG4M%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Canoy%20et%20al.%22%2C%22parsedDate%22%3A%222022-01-20%22%2C%22numChildren%22%3A5%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BCanoy%2C%20D.%2C%20Copland%2C%20E.%2C%20Nazarzadeh%2C%20M.%20et%20al.%20%282022%29.%20Antihypertensive%20drug%20effects%20on%20long-term%20blood%20pressure%3A%20an%20individual-level%20data%20meta-analysis%20of%20randomised%20clinical%20trials.%20%26lt%3Bi%26gt%3BHeart%26lt%3B%5C%2Fi%26gt%3B%2C%20heartjnl-2021-320171.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1136%5C%2Fheartjnl-2021-320171%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1136%5C%2Fheartjnl-2021-320171%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Antihypertensive%20drug%20effects%20on%20long-term%20blood%20pressure%3A%20an%20individual-level%20data%20meta-analysis%20of%20randomised%20clinical%20trials%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dexter%22%2C%22lastName%22%3A%22Canoy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emma%22%2C%22lastName%22%3A%22Copland%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Milad%22%2C%22lastName%22%3A%22Nazarzadeh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rema%22%2C%22lastName%22%3A%22Ramakrishnan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ana-Catarina%22%2C%22lastName%22%3A%22Pinho-Gomes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Abdul%22%2C%22lastName%22%3A%22Salam%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jamie%20P.%22%2C%22lastName%22%3A%22Dwyer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Farshad%22%2C%22lastName%22%3A%22Farzadfar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Johan%22%2C%22lastName%22%3A%22Sundstr%5Cu00f6m%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mark%22%2C%22lastName%22%3A%22Woodward%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Barry%20R.%22%2C%22lastName%22%3A%22Davis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kazem%22%2C%22lastName%22%3A%22Rahimi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22Blood%20Pressure%20Lowering%20Treatment%20Trialists%27%20Collaboration%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22Blood%20Pressure%20Lowering%20Treatment%20Trialists%20Collaboration%22%7D%5D%2C%22abstractNote%22%3A%22OBJECTIVE%3A%20Evidence%20from%20randomised%20trials%20of%20pharmacological%20treatments%20on%20long-term%20blood%20pressure%20%28BP%29%20reduction%20is%20limited.%20We%20investigated%20the%20antihypertensive%20drug%20effects%20on%20BP%20over%20time%20and%20across%20different%20participant%20characteristics.%5CnMETHODS%3A%20We%20conducted%20an%20individual%20patient-level%20data%20meta-analysis%20of%2052%20large-scale%20randomised%20clinical%20trials%20in%20the%20Blood%20Pressure%20Lowering%20Treatment%20Trialists%26%23039%3B%20Collaboration%20using%20mixed%20models%20to%20examine%20treatment%20effects%20on%20BP%20over%204%5Cu2009years%20of%20mean%20follow-up.%5CnRESULTS%3A%20There%20were%20363%5Cu2009684%20participants%20%2842%25%5Cu2009women%29%2C%20with%20baseline%20mean%20age%3D65%20years%20and%20mean%20systolic%5C%2Fdiastolic%20BP%3D152%5C%2F87%5Cu2009mm%20Hg%2C%20and%20among%20whom%2019%25%20were%20current%20smokers%2C%2049%25%20had%20cardiovascular%20disease%2C%2028%25%20had%20diabetes%20and%2069%25%20were%20taking%20antihypertensive%20treatment%20at%20baseline.%20Drugs%20were%20effective%20in%20lowering%20BP%20showing%20maximal%20effect%20after%2012%20months%20and%20gradually%20attenuating%20towards%20later%20years.%20Based%20on%20measures%20taken%20%5Cu226512%20months%20postrandomisation%2C%20mean%20systolic%5C%2Fdiastolic%20BP%20difference%20%2895%25%20CI%29%20between%20more%20and%20less%20intense%20BP-lowering%20treatment%20was%20-11.1%20%28-11.3%20to%20-10.8%29%5C%2F-5.6%20%28-5.7%20to%20-5.4%29%5Cu2009mm%20Hg%3B%20between%20active%20treatment%20and%20placebo%20was%20-5.1%20%28-5.3%20to%20-5.0%29%5C%2F-2.3%20%28-2.4%20to%20-2.2%29%5Cu2009mm%20Hg%3B%20and%20between%20active%20and%20control%20arms%20for%20drug%20comparison%20trials%20was%20-1.4%20%28-1.5%20to%20-1.3%29%5C%2F-0.6%20%28-0.7%20to%20-0.6%29%5Cu2009mm%20Hg.%20BP%20reductions%20were%20observed%20across%20different%20baseline%20BP%20values%20and%20ages%2C%20and%20by%20sex%2C%20history%20of%20cardiovascular%20disease%20and%20diabetes%20and%20prior%20antihypertensive%20treatment%20use.%5CnCONCLUSION%3A%20These%20findings%20suggest%20that%20BP-lowering%20pharmacotherapy%20is%20effective%20in%20lowering%20BP%2C%20up%20to%204%5Cu2009years%20on%20average%2C%20in%20people%20with%20different%20characteristics.%20Appropriate%20treatment%20strategies%20are%20needed%20to%20sustain%20substantive%20long-term%20BP%20reductions.%22%2C%22date%22%3A%222022-01-20%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1136%5C%2Fheartjnl-2021-320171%22%2C%22ISSN%22%3A%221468-201X%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22HVXNQK65%22%2C%22IEPEFS59%22%5D%2C%22dateModified%22%3A%222022-02-04T16%3A45%3A08Z%22%7D%7D%2C%7B%22key%22%3A%22P3D96T53%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Du%20et%20al.%22%2C%22parsedDate%22%3A%222022%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BDu%2C%20X.%20L.%2C%20Simpson%2C%20L.%20M.%2C%20Osani%2C%20M.%20C.%20et%20al.%20%282022%29.%20Risk%20of%20developing%20Alzheimer%26%23x2019%3Bs%20disease%20and%20related%20dementias%20in%20ALLHAT%20trial%20participants%20receiving%20diuretic%2C%20ACE-inhibitor%2C%20or%20calcium-channel%20blocker%20with%2018%20years%20of%20follow-up.%20%26lt%3Bi%26gt%3BJ%20Alzheimers%20Dis%20Parkinsonism%26lt%3B%5C%2Fi%26gt%3B%20%26lt%3Bi%26gt%3B12%26lt%3B%5C%2Fi%26gt%3B%2C%20541%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Risk%20of%20developing%20Alzheimer%27s%20disease%20and%20related%20dementias%20in%20ALLHAT%20trial%20participants%20receiving%20diuretic%2C%20ACE-inhibitor%2C%20or%20calcium-channel%20blocker%20with%2018%20years%20of%20follow-up%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Xianglin%20L.%22%2C%22lastName%22%3A%22Du%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lara%20M.%22%2C%22lastName%22%3A%22Simpson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mikala%20C.%22%2C%22lastName%22%3A%22Osani%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jose-Miguel%22%2C%22lastName%22%3A%22Yama%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Barry%20R.%22%2C%22lastName%22%3A%22Davis%22%7D%5D%2C%22abstractNote%22%3A%22Background%3A%20There%20is%20no%20any%20large%20randomized%20clinical%20trial%20of%20antihypertensive%20drug%20treatment%20with%2018-year%20passive%20follow-up%20to%20examine%20the%20risk%20of%20Alzheimer%26%23039%3Bs%20Disease%20%28AD%29%20or%20Related%20Dementias%20%28ADRD%29.%5CnMethods%3A%20Post-trial%20passive%20follow-up%20study%20of%20Antihypertensive%20and%20Lipid-Lowering%20Treatment%20to%20Prevent%20Heart%20Attack%20Trial%20%28ALLHAT%29%20participants%20in%201994-1998%20by%20linking%20with%20their%20Medicare%20claims%20data%20through%202017%20among%2017%2C158%20subjects%20in%20567%20U.S.%20centers%20who%20were%20free%20of%20ADRD%20at%20baseline%20on%20January%201%2C%201999.%20Main%20outcome%20was%20the%20occurrence%20of%20ADRD%20over%2018%20years%20of%20follow-up.%5CnResults%3A%20The%2018-year%20cumulative%20incidence%20rates%20were%2030.9%25%20for%20AD%2C%2059.2%25%20for%20non-AD%20dementias%2C%20and%2060.9%25%20for%20any%20ADRD.%20The%2018-year%20cumulative%20incidence%20of%20AD%20was%20almost%20identical%20for%20the%203%20drug%20groups%20%2830.5%25%20for%20chlorthalidone%2C%2031.1%25%20for%20amlodipine%2C%20and%2031.4%25%20for%20lisinopril%29.%20The%20hazard%20ratios%20of%20AD%2C%20non-AD%20dementias%20and%20total%20ADRD%20were%20not%20statistically%20significantly%20different%20among%20the%203%20drug%20groups.%20The%20adjusted%20hazard%20ratio%20of%20AD%20was%201.04%20%2895%25%20CI%3A%200.94-1.14%29%20for%20chlorthalidone%20versus%20amlodipine%2C%201.02%20%280.92-1.13%29%20for%20lisinopril%20versus%20amlodipine%2C%20and%200.98%20%280.89-1.08%29%20for%20lisinopril%20versus%20chlorthalidone%2C%20which%20were%20not%20significantly%20different.%20The%20risk%20of%20AD%20and%20non-AD%20dementias%20was%20significantly%20higher%20in%20older%20subjects%2C%20females%2C%20blacks%2C%20non-Hispanics%2C%20subjects%20with%20lower%20education%2C%20and%20subjects%20with%20vascular%20diseases.%5CnConclusion%3A%20The%20risk%20of%20ADRD%20did%20not%20vary%20significantly%20by%203%20antihypertensive%20drugs%20in%20ALLHAT%20trial%20participants%20with%2018-years%20of%20follow-up.%20The%20risk%20of%20ADRD%20was%20significantly%20associated%20with%20age%2C%20gender%2C%20race%5C%2Fethnicity%2C%20education%2C%20and%20history%20of%20vascular%20diseases.%22%2C%22date%22%3A%222022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%22%22%2C%22ISSN%22%3A%222161-0460%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22HVXNQK65%22%2C%22V4E2TPM3%22%5D%2C%22dateModified%22%3A%222022-05-27T13%3A33%3A09Z%22%7D%7D%2C%7B%22key%22%3A%22XA8PY9NE%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Nazarzadeh%20et%20al.%22%2C%22parsedDate%22%3A%222021-11-13%22%2C%22numChildren%22%3A4%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BNazarzadeh%2C%20M.%2C%20Bidel%2C%20Z.%2C%20Canoy%2C%20D.%20et%20al.%20%282021%29.%20Blood%20pressure%20lowering%20and%20risk%20of%20new-onset%20type%202%20diabetes%3A%20an%20individual%20participant%20data%20meta-analysis.%20%26lt%3Bi%26gt%3BLancet%26lt%3B%5C%2Fi%26gt%3B%20%26lt%3Bi%26gt%3B398%26lt%3B%5C%2Fi%26gt%3B%2C%201803%26%23x2013%3B1810.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2FS0140-6736%2821%2901920-6%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2FS0140-6736%2821%2901920-6%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Blood%20pressure%20lowering%20and%20risk%20of%20new-onset%20type%202%20diabetes%3A%20an%20individual%20participant%20data%20meta-analysis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Milad%22%2C%22lastName%22%3A%22Nazarzadeh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Zeinab%22%2C%22lastName%22%3A%22Bidel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dexter%22%2C%22lastName%22%3A%22Canoy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emma%22%2C%22lastName%22%3A%22Copland%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Malgorzata%22%2C%22lastName%22%3A%22Wamil%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jeannette%22%2C%22lastName%22%3A%22Majert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Karl%22%2C%22lastName%22%3A%22Smith%20Byrne%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Johan%22%2C%22lastName%22%3A%22Sundstr%5Cu00f6m%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Koon%22%2C%22lastName%22%3A%22Teo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Barry%20R.%22%2C%22lastName%22%3A%22Davis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22John%22%2C%22lastName%22%3A%22Chalmers%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carl%20J.%22%2C%22lastName%22%3A%22Pepine%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Abbas%22%2C%22lastName%22%3A%22Dehghan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Derrick%20A.%22%2C%22lastName%22%3A%22Bennett%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22George%20Davey%22%2C%22lastName%22%3A%22Smith%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kazem%22%2C%22lastName%22%3A%22Rahimi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22Blood%20Pressure%20Lowering%20Treatment%20Trialists%5Cu2019%20Collaboration%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Blood%20pressure%20lowering%20is%20an%20established%20strategy%20for%20preventing%20microvascular%20and%20macrovascular%20complications%20of%20diabetes%2C%20but%20its%20role%20in%20the%20prevention%20of%20diabetes%20itself%20is%20unclear.%20We%20aimed%20to%20examine%20this%20question%20using%20individual%20participant%20data%20from%20major%20randomised%20controlled%20trials.%5CnMETHODS%3A%20We%20performed%20a%20one-stage%20individual%20participant%20data%20meta-analysis%2C%20in%20which%20data%20were%20pooled%20to%20investigate%20the%20effect%20of%20blood%20pressure%20lowering%20per%20se%20on%20the%20risk%20of%20new-onset%20type%202%20diabetes.%20An%20individual%20participant%20data%20network%20meta-analysis%20was%20used%20to%20investigate%20the%20differential%20effects%20of%20five%20major%20classes%20of%20antihypertensive%20drugs%20on%20the%20risk%20of%20new-onset%20type%202%20diabetes.%20Overall%2C%20data%20from%2022%20studies%20conducted%20between%201973%20and%202008%2C%20were%20obtained%20by%20the%20Blood%20Pressure%20Lowering%20Treatment%20Trialists%26%23039%3B%20Collaboration%20%28Oxford%20University%2C%20Oxford%2C%20UK%29.%20We%20included%20all%20primary%20and%20secondary%20prevention%20trials%20that%20used%20a%20specific%20class%20or%20classes%20of%20antihypertensive%20drugs%20versus%20placebo%20or%20other%20classes%20of%20blood%20pressure%20lowering%20medications%20that%20had%20at%20least%201000%20persons-years%20of%20follow-up%20in%20each%20randomly%20allocated%20arm.%20Participants%20with%20a%20known%20diagnosis%20of%20diabetes%20at%20baseline%20and%20trials%20conducted%20in%20patients%20with%20prevalent%20diabetes%20were%20excluded.%20For%20the%20one-stage%20individual%20participant%20data%20meta-analysis%20we%20used%20stratified%20Cox%20proportional%20hazards%20model%20and%20for%20the%20individual%20participant%20data%20network%20meta-analysis%20we%20used%20logistic%20regression%20models%20to%20calculate%20the%20relative%20risk%20%28RR%29%20for%20drug%20class%20comparisons.%5CnFINDINGS%3A%20145%5Cu2008939%20participants%20%2888%5Cu2008500%20%5B60%5Cu00b76%25%5D%20men%20and%2057%5Cu2008429%20%5B39%5Cu00b74%25%5D%20women%29%20from%2019%20randomised%20controlled%20trials%20were%20included%20in%20the%20one-stage%20individual%20participant%20data%20meta-analysis.%2022%20trials%20were%20included%20in%20the%20individual%20participant%20data%20network%20meta-analysis.%20After%20a%20median%20follow-up%20of%204%5Cu00b75%20years%20%28IQR%202%5Cu00b70%29%2C%209883%20participants%20were%20diagnosed%20with%20new-onset%20type%202%20diabetes.%20Systolic%20blood%20pressure%20reduction%20by%205%20mm%20Hg%20reduced%20the%20risk%20of%20type%202%20diabetes%20across%20all%20trials%20by%2011%25%20%28hazard%20ratio%200%5Cu00b789%20%5B95%25%20CI%200%5Cu00b784-0%5Cu00b795%5D%29.%20Investigation%20of%20the%20effects%20of%20five%20major%20classes%20of%20antihypertensive%20drugs%20showed%20that%20in%20comparison%20to%20placebo%2C%20angiotensin-converting%20enzyme%20inhibitors%20%28RR%200%5Cu00b784%20%5B95%25%200%5Cu00b776-0%5Cu00b793%5D%29%20and%20angiotensin%20II%20receptor%20blockers%20%28RR%200%5Cu00b784%20%5B0%5Cu00b776-0%5Cu00b792%5D%29%20reduced%20the%20risk%20of%20new-onset%20type%202%20diabetes%3B%20however%2C%20the%20use%20of%20%5Cu03b2%20blockers%20%28RR%201%5Cu00b748%20%5B1%5Cu00b727-1%5Cu00b772%5D%29%20and%20thiazide%20diuretics%20%28RR%201%5Cu00b720%20%5B1%5Cu00b707-1%5Cu00b735%5D%29%20increased%20this%20risk%2C%20and%20no%20material%20effect%20was%20found%20for%20calcium%20channel%20blockers%20%28RR%201%5Cu00b702%20%5B0%5Cu00b792-1%5Cu00b713%5D%29.%5CnINTERPRETATION%3A%20Blood%20pressure%20lowering%20is%20an%20effective%20strategy%20for%20the%20prevention%20of%20new-onset%20type%202%20diabetes.%20Established%20pharmacological%20interventions%2C%20however%2C%20have%20qualitatively%20and%20quantitively%20different%20effects%20on%20diabetes%2C%20likely%20due%20to%20their%20differing%20off-target%20effects%2C%20with%20angiotensin-converting%20enzyme%20inhibitors%20and%20angiotensin%20II%20receptor%20blockers%20having%20the%20most%20favourable%20outcomes.%20This%20evidence%20supports%20the%20indication%20for%20selected%20classes%20of%20antihypertensive%20drugs%20for%20the%20prevention%20of%20diabetes%2C%20which%20could%20further%20refine%20the%20selection%20of%20drug%20choice%20according%20to%20an%20individual%26%23039%3Bs%20clinical%20risk%20of%20diabetes.%5CnFUNDING%3A%20British%20Heart%20Foundation%2C%20National%20Institute%20for%20Health%20Research%2C%20and%20Oxford%20Martin%20School.%22%2C%22date%22%3A%22Nov%2013%202021%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2FS0140-6736%2821%2901920-6%22%2C%22ISSN%22%3A%221474-547X%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22HVXNQK65%22%5D%2C%22dateModified%22%3A%222022-01-24T22%3A48%3A54Z%22%7D%7D%2C%7B%22key%22%3A%22AGBTDZ2D%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Bowling%20et%20al.%22%2C%22parsedDate%22%3A%222021-11-01%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BBowling%2C%20C.%20B.%2C%20Sloane%2C%20R.%2C%20Pieper%2C%20C.%20et%20al.%20%282021%29.%20Sustained%20SBP%20control%20and%20long-term%20nursing%20home%20admission%20among%20Medicare%20beneficiaries.%20%26lt%3Bi%26gt%3BJ%20Hypertens%26lt%3B%5C%2Fi%26gt%3B%20%26lt%3Bi%26gt%3B39%26lt%3B%5C%2Fi%26gt%3B%2C%202258%26%23x2013%3B2264.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FHJH.0000000000002926%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FHJH.0000000000002926%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Sustained%20SBP%20control%20and%20long-term%20nursing%20home%20admission%20among%20Medicare%20beneficiaries%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%20Barrett%22%2C%22lastName%22%3A%22Bowling%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Richard%22%2C%22lastName%22%3A%22Sloane%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carl%22%2C%22lastName%22%3A%22Pieper%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alison%22%2C%22lastName%22%3A%22Luciano%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Barry%20R.%22%2C%22lastName%22%3A%22Davis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lara%20M.%22%2C%22lastName%22%3A%22Simpson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Paula%20T.%22%2C%22lastName%22%3A%22Einhorn%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Suzanne%22%2C%22lastName%22%3A%22Oparil%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Paul%22%2C%22lastName%22%3A%22Muntner%22%7D%5D%2C%22abstractNote%22%3A%22OBJECTIVES%3A%20Sustaining%20SBP%20control%20reduces%20the%20risk%20for%20cardiovascular%20events%20that%20impair%20function%20but%20its%20association%20with%20nursing%20home%20admission%20has%20not%20been%20well%20studied.%5CnMETHODS%3A%20We%20conducted%20an%20analysis%20of%20sustained%20SBP%20control%20and%20long-term%20nursing%20home%20admissions%20using%20data%20from%20the%20Antihypertensive%20and%20Lipid-Lowering%20Treatment%20to%20Prevent%20Heart%20Attack%20Trial%20%28ALLHAT%29%20linked%20to%20Medicare%20claims%20restricted%20to%20participants%20with%20fee-for-service%20coverage%2C%20at%20least%20eight%20study%20visits%20with%20SBP%20measurements%2C%20who%20were%20not%20living%20in%20a%20nursing%20home%20during%20a%2048-month%20baseline%20BP%20assessment%20period%20%28n%5Cu200a%3D%5Cu200a6557%29.%20Sustained%20SBP%20control%20was%20defined%20as%20less%20than%20140%5Cu200ammHg%20at%20less%20than%2050%25%2C%2050%25%20to%20less%20than%2075%25%2C%2075%25%20to%20less%20than%20100%25%2C%20and%20100%25%20of%20visits.%20Nursing%20home%20admissions%20were%20identified%20using%20the%20Medicare%20Long%20Term%20Care%20Minimum%20Data%20Set.%5CnRESULTS%3A%20The%20mean%20age%20of%20participants%20was%2073.8%5Cu200ayears%20and%2044.3%25%20were%20men.%20Over%20a%20median%20follow-up%20of%209.2%5Cu200ayears%2C%20844%20participants%20%2812.8%25%29%20had%20a%20nursing%20home%20admission.%20Rates%20of%20nursing%20home%20admission%20per%20100%20person-years%20were%2016.3%20for%20participants%20with%20SBP%20control%20at%20less%20than%2050%25%2C%2014.1%20at%2050%25%20to%20less%20than%2075%25%2C%207.8%20at%2075%25%20to%20less%20than%20100%25%2C%20and%205.3%20at%20100%25%20of%20visits.%20Compared%20with%20those%20with%20sustained%20SBP%20control%20at%20less%20than%2050%25%20of%20visits%2C%20hazard%20ratios%20%2895%25%20confidence%20intervals%29%20for%20nursing%20home%20admission%20were%200.79%20%280.66-0.93%29%2C%200.70%20%280.58-0.84%29%2C%20and%200.57%20%280.44-0.74%29%20among%20participants%20with%20SBP%20control%20at%2050%25%20to%20less%20than%2075%25%2C%2075%25%20to%20less%20than%20100%25%2C%20and%20100%25%20of%20visits%2C%20respectively.%5CnCONCLUSION%3A%20Among%20Medicare%20beneficiaries%20in%20ALLHAT%2C%20sustained%20SBP%20control%20was%20associated%20with%20a%20lower%20risk%20of%20long-term%20nursing%20home%20admission.%22%2C%22date%22%3A%222021-11-01%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1097%5C%2FHJH.0000000000002926%22%2C%22ISSN%22%3A%221473-5598%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22HVXNQK65%22%5D%2C%22dateModified%22%3A%222022-01-24T22%3A46%3A31Z%22%7D%7D%2C%7B%22key%22%3A%22THCZA3ME%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Woodhouse%20et%20al.%22%2C%22parsedDate%22%3A%222021-10-17%22%2C%22numChildren%22%3A4%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BWoodhouse%2C%20L.%20J.%2C%20Montgomery%2C%20A.%20A.%2C%20Mant%2C%20J.%20et%20al.%20%282021%29.%20Statistical%20reanalysis%20of%20vascular%20event%20outcomes%20in%20primary%20and%20secondary%20vascular%20prevention%20trials.%20%26lt%3Bi%26gt%3BBMC%20Med%20Res%20Methodol%26lt%3B%5C%2Fi%26gt%3B%20%26lt%3Bi%26gt%3B21%26lt%3B%5C%2Fi%26gt%3B%2C%20218.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs12874-021-01388-6%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs12874-021-01388-6%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Statistical%20reanalysis%20of%20vascular%20event%20outcomes%20in%20primary%20and%20secondary%20vascular%20prevention%20trials%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lisa%20J.%22%2C%22lastName%22%3A%22Woodhouse%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alan%20A.%22%2C%22lastName%22%3A%22Montgomery%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jonathan%22%2C%22lastName%22%3A%22Mant%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Barry%20R.%22%2C%22lastName%22%3A%22Davis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ale%22%2C%22lastName%22%3A%22Algra%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Louis%22%2C%22lastName%22%3A%22Mas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jan%20A.%22%2C%22lastName%22%3A%22Staessen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lutgarde%22%2C%22lastName%22%3A%22Thijs%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andrew%22%2C%22lastName%22%3A%22Tonkin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adrienne%22%2C%22lastName%22%3A%22Kirby%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stuart%20J.%22%2C%22lastName%22%3A%22Pocock%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22John%22%2C%22lastName%22%3A%22Chalmers%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Graeme%20J.%22%2C%22lastName%22%3A%22Hankey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20David%22%2C%22lastName%22%3A%22Spence%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Peter%22%2C%22lastName%22%3A%22Sandercock%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hans-Christoph%22%2C%22lastName%22%3A%22Diener%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Shinichiro%22%2C%22lastName%22%3A%22Uchiyama%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nikola%22%2C%22lastName%22%3A%22Sprigg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philip%20M.%22%2C%22lastName%22%3A%22Bath%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Vascular%20prevention%20trials%20typically%20use%20dichotomous%20event%20outcomes%20although%20this%20may%20be%20inefficient%20statistically%20and%20gives%20no%20indication%20of%20event%20severity.%20We%20assessed%20whether%20ordinal%20outcomes%20would%20be%20more%20efficient%20and%20how%20to%20best%20analyse%20them.%5CnMETHODS%3A%20Chief%20investigators%20of%20vascular%20prevention%20randomised%20controlled%20trials%20that%20showed%20evidence%20of%20either%20benefit%20or%20harm%2C%20or%20were%20included%20in%20a%20systematic%20review%20that%20overall%20showed%20benefit%20or%20harm%2C%20shared%20individual%20participant%20data%20from%20their%20trials.%20Ordered%20categorical%20versions%20of%20vascular%20event%20outcomes%20%28such%20as%20stroke%20and%20myocardial%20infarction%29%20were%20analysed%20using%2015%20statistical%20techniques%20and%20their%20results%20then%20ranked%2C%20with%20the%20result%20with%20the%20smallest%20p-value%20given%20the%20smallest%20rank.%20Friedman%20and%20Duncan%26%23039%3Bs%20multiple%20range%20tests%20were%20performed%20to%20assess%20differences%20between%20tests%20by%20comparing%20the%20average%20ranks%20for%20each%20statistical%20test.%5CnRESULTS%3A%20Data%20from%2035%20trials%20%28254%2C223%20participants%29%20were%20shared%20with%20the%20collaboration.%2013%20trials%20had%20more%20than%20two%20treatment%20arms%2C%20resulting%20in%2059%20comparisons.%20Analysis%20approaches%20%28Mann%20Whitney%20U%2C%20ordinal%20logistic%20regression%2C%20multiple%20regression%2C%20bootstrapping%29%20that%20used%20ordinal%20outcome%20data%20had%20a%20smaller%20average%20rank%20and%20therefore%20appeared%20to%20be%20more%20efficient%20statistically%20than%20those%20that%20analysed%20the%20original%20binary%20outcomes.%5CnCONCLUSIONS%3A%20Ordinal%20vascular%20outcome%20measures%20appear%20to%20be%20more%20efficient%20statistically%20than%20binary%20outcomes%20and%20provide%20information%20on%20the%20severity%20of%20event.%20We%20suggest%20a%20potential%20role%20for%20using%20ordinal%20outcomes%20in%20vascular%20prevention%20trials.%22%2C%22date%22%3A%22Oct%2017%202021%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1186%5C%2Fs12874-021-01388-6%22%2C%22ISSN%22%3A%221471-2288%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22HVXNQK65%22%5D%2C%22dateModified%22%3A%222022-01-24T22%3A54%3A00Z%22%7D%7D%5D%7D

Bidel, Z., Nazarzadeh, M., Canoy, D. et al. (2023). Sex-specific effects of blood pressure lowering pharmacotherapy for the prevention of cardiovascular disease: an individual participant-level data meta-analysis. Hypertension. https://doi.org/10.1161/HYPERTENSIONAHA.123.21496.

Ghosh, A., Chan, W., Younes, N. et al. (2022). A dynamic risk model for multitype recurrent events. Am J Epidemiol, kwac213. https://doi.org/10.1093/aje/kwac213.

Nazarzadeh, M., Bidel, Z., Canoy, D. et al. (2022). Blood pressure-lowering treatment for prevention of major cardiovascular diseases in people with and without type 2 diabetes: an individual participant-level data meta-analysis. Lancet Diabetes Endocrinol, S2213-8587(22)00172–3. https://doi.org/10.1016/S2213-8587(22)00172-3.

Kaushal, S., Hare, J. M., Shah, A. M. et al. (2022). Autologous cardiac stem cell injection in patients with hypoplastic left heart syndrome (CHILD Study). Pediatr Cardiol. https://doi.org/10.1007/s00246-022-02872-6.

Nazarzadeh, M., Canoy, D., Bidel, Z. et al. (2022). The Blood Pressure Lowering Treatment Trialists’ Collaboration: Methodological clarifications of recent reports. J Hypertens. https://doi.org/10.1097/HJH.0000000000003107.

Canoy, D., Copland, E., Nazarzadeh, M. et al. (2022). Antihypertensive drug effects on long-term blood pressure: an individual-level data meta-analysis of randomised clinical trials. Heart, heartjnl-2021-320171. https://doi.org/10.1136/heartjnl-2021-320171.

Du, X. L., Simpson, L. M., Osani, M. C. et al. (2022). Risk of developing Alzheimer’s disease and related dementias in ALLHAT trial participants receiving diuretic, ACE-inhibitor, or calcium-channel blocker with 18 years of follow-up. J Alzheimers Dis Parkinsonism 12, 541

Nazarzadeh, M., Bidel, Z., Canoy, D. et al. (2021). Blood pressure lowering and risk of new-onset type 2 diabetes: an individual participant data meta-analysis. Lancet 398, 1803–1810. https://doi.org/10.1016/S0140-6736(21)01920-6.

Bowling, C. B., Sloane, R., Pieper, C. et al. (2021). Sustained SBP control and long-term nursing home admission among Medicare beneficiaries. J Hypertens 39, 2258–2264. https://doi.org/10.1097/HJH.0000000000002926.

Woodhouse, L. J., Montgomery, A. A., Mant, J. et al. (2021). Statistical reanalysis of vascular event outcomes in primary and secondary vascular prevention trials. BMC Med Res Methodol 21, 218. https://doi.org/10.1186/s12874-021-01388-6.

Interests

Education

Undergraduate:

Postgraduate:

Medical School:

Internship:

Academic & Clinical Affiliations

Certifications

Honors, Awards and Memberships

Publications